Evidence map›Paper›PMID 38970152›Full record

ArticleACS applied bio materials2024

Degree of PEGylatation of

Carlos J Munoz, Daniela Lucas, Cynthia R Muller, Amanda Breton, Vinay Jani, Chintan Savla, Andre F Palmer, Pedro Cabrales

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied bio materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carlos J MunozDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-4832-3661
Daniela LucasDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0009-0005-0101-4628
Cynthia R MullerDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.
Amanda BretonDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.
Vinay JaniDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.
Chintan SavlaWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States.ORCID 0000-0001-7538-8861
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States.
Pedro CabralesDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-8794-2839

Funding

Integrative Bioengineering of Heart, Vessels, and BloodT32HL105373 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, INTAGLIETTA, MARCOS · 2010 to 2019
$3.6M
PEGylated megahemoglobin for use as a red blood cell substituteR01HL138116 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, KAUMAYA, PRAVIN T. P. · 2017 to 2020
$2.9M
Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Attenuating the Oxidative and Myocardial Side-Effects of Acellular HemoglobinR01HL126945 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.7M
Training in Bioengineering Research and Technology Development in Cardiovascular in Cardiopulmonary Health and DiseaseT32HL160507 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karen L Christman, Andrew D. McCulloch · 2022 to 2026
$1.6M
NHLBI NIH HHS R01 HL126945NHLBI NIH HHS R01 HL138116NHLBI NIH HHS R01 HL159862NHLBI NIH HHS T32 HL105373NHLBI NIH HHS T32 HL160507
6 · The paper itself

Abstract

introductionThe demand for red blood cells (RBCs) is on the rise due to the increasing diagnosis of chronic diseases such as sickle cell anemia, malaria, and thalassemia. Despite many commercial attempts, there are no U.S. FDA-approved artificial RBCs for use in humans. Existing RBC substitutes have employed various strategies to transport oxygen, extend the circulation time, and reduce organ toxicity, but none have replicated the natural protective mechanisms of RBCs, which prevent hemoglobin (Hb) dimerization and heme iron oxidation.

methodsWe conducted experiments using golden Syrian hamsters with dorsal window chambers and catheters to assess the efficacy of these solutions. We measured microvascular parameters, organ function, cerebral blood flow, circulation time, mean arterial pressure, heart rate, and blood gases and performed histology to screen for toxicity.

conclusionOur findings indicate that both PEG-LtEc molecules offer significant benefits in restoring microvascular parameters, organ function, cerebral blood flow, and circulation time compared to LtEc alone. Notably, PEG-LtEc-1.0 showed superior microvascular perfusion, although it exhibited a higher rate of auto-oxidation compared to PEG-LtEc-0.2. These results underscore the advantages of PEGylation in terms of tissue perfusion and organ health while highlighting its limitations.

Indexed as

ErythrocytesHemoglobinsOligochaetaAnimalsBiocompatible MaterialsMaterials TestingMesocricetusMicrocirculationOxidation-ReductionParticle SizePolyethylene GlycolsBiocompatible MaterialserythrocruorinHemoglobinsPolyethylene Glycols1 Lumbricus terrestris erythrocruorin (LtEc)2 PEGlyation3 microcirculation4 hemoglobin-based oxygen carriers (HBOC)5 oxidation rate

Identifiers

PMID38970152
PMCPMC12802512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.